These findings suggest that the antitumor efficacy of the Sulfatinib and Kaempferol combination is achieved through a dual inhibition mechanism of the PI3K/AKT/mTOR signaling pathway, alongside functional interactions with CALCA, a principal regulator within the pathway, thereby synergistically thwarting tumor development. The gene discussed is MTOR; the disease is neoplasm.